Sentences with phrase «conditions from developing»

An important step in proper dog pet care is bathing your dog on a regular basis, doing so can prevent some serious skin conditions from developing.

You can prevent some conditions from developing (like allergies) by giving your dog the correct food.

Early treatment can stop some conditions from developing and help prevent later complications.

Thus antioxidants can play a role in the prevention of serious health conditions from developing or worsening.

In doing so, we can help prevent serious medical conditions from developing in the future.

Once a person is a Type 1 diabetic, healing the gut will not cure the condition, but it may help prevent other auto - immune conditions from developing as well.

The high amount of fiber in bananas can help prevent many respiratory conditions from developing, or alleviate their symptoms at the very least.

«Unless policymakers act now to support these centers, many low - income Americans will be left without the high - quality care that can prevent many expensive health conditions from developing in the first place.»

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

All of these symptoms of stress play key roles in the development of diabetes, and, if managed properly, can prevent the condition from developing or even turn the tide against it.

In all such circumstances, municipalities can take appropriate preventative steps to prevent a poor road condition from developing and based on Giuliani v. Halton can not wait until the appropriate accumulation has arisen before the time period within which they must act begins to run.

Not exact matches

Doing business in less - developed country is always going to pose a range of challenges, from corrupt officials to bad infrastructure to non-existent environmental regulations and shoddy labour conditions.

• Menlo Therapeutics, a Redwood City, Calif. - based biotech developing therapies for pruritus associated with dermatologic conditions, now says it plans to raise $ 107 million in an offering 6.5 million shares at between $ 16 to $ 17 a piece, up from a previous stated 5.7 million shares priced between $ 14 to $ 16.

«At the same time, there are clear downside risks: political uncertainty, including in Europe; the sword of protectionism hanging over global trade; and tighter global financial conditions that could trigger disruptive capital outflows from emerging and developing economies,» the former French finance minister said.

At last year's Brainstorm Health conference in San Diego, Bergh found himself sitting at dinner with Othman Laraki, the cofounder and CEO of Color Genomics — a company that extracts the DNA from a customer's submitted saliva sample and then looks for a set number of gene mutations known to be associated with increased risk for developing certain hereditary cancers or heart conditions (depending on the test).

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

Gates discussed the foundation's efforts to improve conditions in developing areas, where she» [goes] in as an anonymous woman from the West in khakis and a T - shirt» to listen to residents.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

Deprived of it, they quickly develop medical conditions from a lack of essential amino acids.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These risks and uncertainties include competition and other economic conditions including fragmentation of the media landscape and competition from other media alternatives; changes in advertising demand, circulation levels and audience shares; the Company's ability to develop and grow its online businesses; the Company's reliance on revenue from printing and distributing third - party publications; changes in newsprint prices; macroeconomic trends and conditions; the Company's ability to adapt to technological changes; the Company's ability to realize benefits or synergies from acquisitions or divestitures or to operate its businesses effectively following acquisitions or divestitures; the Company's success in implementing expense mitigation efforts; the Company's reliance on third - party vendors for various services; adverse results from litigation, governmental investigations or tax - related proceedings or audits; the Company's ability to attract and retain employees; the Company's ability to satisfy pension and other postretirement employee benefit obligations; changes in accounting standards; the effect of labor strikes, lockouts and labor negotiations; regulatory and judicial rulings; the Company's indebtedness and ability to comply with debt covenants applicable to its debt facilities; the Company's ability to satisfy future capital and liquidity requirements; the Company's ability to access the credit and capital markets at the times and in the amounts needed and on acceptable terms; and other events beyond the Company's control that may result in unexpected adverse operating results.

In 2015, Starbucks will donate thousands of seedlings from five different coffee tree hybrids developed through its research to ICAFE which will then be verified in different regions of Costa Rica most impacted by these challenging conditions.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

In addition to «flat - fee - only» and «fee - offset» models, the SunAmerica Advisory Opinion provides that asset allocation services offered to participants (involving advice and even discretionary management) that are the product of a computer model developed and overseen by an independent financial expert, and subject to certain additional conditions, would allow a service provider (the broker - dealer, in this case) to avoid PTs when receiving variable / indirect compensation from its platform of investment offerings.

R. G. Collingwood, in his well - known book, The Idea of Nature, develops the thesis that the idea of nature in philosophical discussion has always been conditioned by historical preoccupations and circumstances.1 We can not hope to isolate nature from our historicity so as to describe clearly and distinctly what it is «in itself.»

Under liberalism, human beings increasingly live in a condition of autonomy such as that first imagined by theorists of the state of nature, except that the anarchy that threatens to develop from that purportedly natural condition is controlled and suppressed through the imposition of laws and the corresponding growth of the state.

a Paul appeals to the evidence of the Spirit in the Church as a datum from which he may argue regarding the nature and conditions of salvation in Christ, and on this basis he develops his doctrine of the Spirit as the «earnest,» or first instalment, of the consummated life of the Age to Come (a Cor.

What this means is that the condition of being unable to understand what Jesus is saying is not something that the Jewish people began with from birth, but is a condition that developed over time as they continued to deny the truth they had heard and ignored the signs they had seen.

It is precisely because of his Christology — one that sees the Christ - event arising from no prior conditions and plotted against no prior coordinates (2:20; 6:14)-- that Paul develops his peculiar understanding of Gentiles» freedom from the requirement of becoming Jewish proselytes.

Because the driving conditions can be vastly different from market to market, Southern Wine & Spirits developed a specific set of criteria for each market to allow the company to choose the right truck for each situation.

Lutein studies report that 10 milligrams of lutein from supplements or dietary sources improves visual function and can help reduce the risk of developing certain eye conditions as you age.

Their temporary migrant workers from the surrounding developing economies are also covered by the same living and working conditions as the local resident workers.

Cellaring The wine will benefit from 6 to 8 months maturation in bottle to allow the fruit to emerge; secondary characters will develop over a 2 to 5 year period when stored under optimum cellaring conditions.

Young children with vitamin A deficiency also have impaired immune systems, a condition which increases the risk of death from certain common childhood infections and claims the lives of 670,000 children each year who live in less developed countries.

In this technique the extra nutrients will be added to the food that is not harmful for the humans and those food will be less open to the severe environmental conditions and from harmful microorganisms.Nowadays new protein food, new methods of food fortification, food adulteration etc are developed to increase the health value.

At the time, infant milk formula was found to contain this substance; many babies in China developed kidney stones and four died from the condition.

Mr Casella hoped wineries benefiting from improving currency conditions would reinvest some profit in to developing export markets.

I have worked with and developed some of the Strongest, Fastest most Well - Conditioned athletes in 25 plus sports from Youth, Amateur, National, Olympic and Professional from Canada to the US.

And so I'm doing my best to be aware that the condition I'm in now took years and years to develop and it is going to take a long time to heal from as well.

One of the leading medications on the market is Imitrex that was developed to ease migraines in those suffering from this often debilitating condition.

Unmanaged preeclampsia can prevent a developing fetus from getting enough blood and oxygen, damage a mother's liver and kidneys, and, in rare cases, progress to eclampsia, a much more serious condition involving seizures.

Studies have consistently failed to prove any decrease in developing allergic conditions in babyhood (and in childhood) stemming from soy compared with cow's milk formula.

If you suffer from a preexisting health condition or develop complications during pregnancy, the number of visits may go up significantly.

Compression shirts for gynecomastia have gained increasing popularity in developed countries due to the number of people who suffer from the condition.

Although there have been several studies into preventing postnatal depression, there is no evidence that there's anything specific you can do to prevent the condition developing, apart from maintaining as healthy a lifestyle as you can for yourself.

You can make changes to your life to both protect your child from developing the condition, or keep her asthma attacks at bay.

These include increased prevalence of a range of infectious diseases and health conditions — ear infections, gastrointestinal infections respiratory infections, necrotizing enterocolitis, sepsis, meningitis, diabetes, childhood cancers, obesity, allergies — formula fed infants grow and develop differently from breastmilk fed infants, including cognitive and neural development.

But if you feel that the condition worsens from time to time and you can no longer handle it, then better consult your obstetrician or your psychologist, for you might be developing maternal depression.

Not only that, it's also good for the mother and keeps her safe from developing various conditions and diseases, and it serves as a factor for bonding between mother and child.